| Literature DB >> 35187173 |
Melanie Boltzmann1, Simone B Schmidt1, Jens D Rollnik1.
Abstract
The present study was aimed at examining thyroid hormones and other clinical factors to improve the accuracy of outcome prediction among critically ill patients undergoing early neurological rehabilitation. Patients consecutively admitted to an intensive or intermediate care unit were screened for eligibility. Serum levels of free triiodothyronine (fT3), free thyroxine (fT4), and thyroid-stimulating hormone (TSH) were collected during the first three days after admission. The Glasgow Outcome Scale (GOS) was defined as the primary outcome measure. Thyroid hormone levels and other clinical factors were entered into a binary logistic regression model to predict a good outcome at the end of early rehabilitative treatment. 395 patients (268 males) with a median age of 62 years (IQR = 52 - 76) and a median disease duration of 19 days (IQR = 13 - 28) were included in the study. Most patients (80%) had decreased fT3 values. Patients with low fT3 were admitted earlier to the rehabilitation facility and had more severe impairment upon admission compared to patients with fT3 values within the normal range. Both decreased fT3 and TSH levels were associated with an unfavorable outcome (GOS ≤ 3), but only TSH proved to be an independent predictor in multivariate analyses (OR = 1.11; 95%CI = 1.02 - 1.22). These data suggest that decreased fT3 and TSH levels upon admission may predict an unfavorable outcome at the end of early rehabilitative treatment. Thus, thyroid hormone levels are not only important during acute treatment but also in prolonged critical illness.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35187173 PMCID: PMC8853786 DOI: 10.1155/2022/8447080
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Comparison of fT3, fT4, and TSH in different etiologies (vascular, traumatic, and anoxic). Note. ∗p < .05 (Mann-Whitney U test); fT3 = free triiodothyronine, fT4 = free thyroxine, TSH = thyroid-stimulating hormone
Comparison of fT3, fT4, and TSH for patients with an unfavorable (GOS ≤ 3) and a favorable (GOS > 3) outcome.
| Primary outcome measure | |||
|---|---|---|---|
| GOS ≤ 3 | GOS > 3 |
| |
| fT3 (pg/ml) | 1.70 (1.31-2.07) | 1.83 (1.50-2.18) | .020a |
| fT4 (pg/ml) | 11.8 (10.3-13.7) | 12.3 (10.9-13.7) | .179a |
| TSH (mU/l) | 1.67 (0.99-2.64) | 1.90 (1.13-3.03) | .048a |
aMann-Whitney U test (GOS ≤ 3 vs GOS > 3). GOS = Glasgow Outcome Scale, fT3 = free triiodothyronine, fT4 = free thyroxine, TSH = thyroid-stimulating hormone.
Patient characteristics for patients with low versus normal fT3 values.
| Low fT3 (<2.18 pg/ml) ( | Normal fT3 (2.18-3.98 pg/ml) ( |
| |
|---|---|---|---|
| Age at event (years) | 64 (53-76) | 59 (49-72) | .059a |
| Time since injury (days) | 18 (12-27) | 20 (17-32) | .005a |
| Male | 212 | 56 | .923b |
| Admission to ICU/IMC | 220/93 | 45/37 | .008b |
|
| |||
| Vascular | 188 | 44 | .294b |
| Traumatic | 98 | 27 | .779b |
| Anoxic | 27 | 11 | .191b |
| Localization (left/right/bilateral) | 102/102/109 | 27/28/27 | .943b |
| BI | 10 (10-10) | 10 (10-15) | .005a |
| EFA | 33 (27-43) | 38 (31-50) | .001a |
| CRS-R | 7 (3-14) | 10 (6-21) | .003a |
| Complications | 30 (24-36) | 26 (23-31) | <.001a |
| Hypophysis dysfunction (y/n) | 18/295 | 2/80 | .223b |
|
| |||
| fT3 (pg/ml) | 1.60 (1.24-1.84) | 2.50 (2.31-2.77) | <.001a |
| fT4 (pg/ml) | 11.5 (9.9-11.5) | 13.8 (12.4-15.4) | <.001a |
| TSH (mU/l) | 1.72 (0.99-2.86) | 1.90 (1.13-2.67) | .726a |
| LOS (days) | 84 (47-113) | 70 (39-106) | .121a |
| GOS | 3 (2-3) | 3 (3-3) | .084a |
aMann-Whitney U test (low vs normal fT3); bChi2 test. BI = Barthel Index, CRS-R = Coma Recovery Scale-Revised, EFA = Early Functional Abilities, fT3 = free triiodothyronine, fT4 = free thyroxine, GOS = Glasgow Outcome Scale, ICU = intensive care unit, IMC = intermediate care unit, LOS = length of stay, TSH = thyroid-stimulating hormone.
Patient characteristics for patients with low, normal and high TSH values.
| Low TSH (<0.34 mU/l) ( | Normal TSH (0.34-4.82 mU/l) ( | High TSH (>4.82 mU/l) ( |
| |
|---|---|---|---|---|
| Age at event (years) | 70 (56-79) | 62 (52-76) | 61 (53-71) | .218a |
| Time since injury (days) | 17 (10-24) | 19 (13-28) | 23 (17-31) | .144a |
| Male | 14 | 233 | 21 | .315b |
| Admission to ICU/IMC | 13/7 | 223/115 | 29/8 | .307b |
|
| ||||
| Vascular | 15 | 198 | 19 | .221b |
| Traumatic | 2 | 107 | 16 | .036b |
| Anoxic | 3 | 33 | 2 | .489b |
| Localization (left/right/bilateral) | 7/6/7 | 109/114/115 | 13/10/14 | .942b |
| BI | 10 (10-10) | 10 (10-15) | 10 (10-10) | .116a |
| EFA | 34 (27-42) | 34 (27-44) | 35 (29-44) | .917a |
| CRS-R | 6 (3-14) | 8 (4-14) | 12 (5-19) | .290a |
| Complications | 29 (24-35) | 29 (23-35) | 28 (25-36) | .816a |
| Hypophysis dysfunction (y/n) | 1/19 | 320/18 | 36/1 | .788b |
|
| ||||
| fT3 (pg/ml) | 1.81 (1.27-2.17) | 1.75 (1.39-2.08) | 1.76 (1.10-2.06) | .589a |
| fT4 (pg/ml) | 12.7 (10.5-15.4) | 12.0 (10.5-13.6) | 10.6 (9.2-13.7) | .056a |
| TSH (mU/l) | 0.19 (0.13-0.29) | 1.68 (1.10-2.26) | 5.48 (4.40-7.25) | <.001a |
| LOS (days) | 69 (30-100) | 83 (49-113) | 63 (41-105) | .244a |
| GOS | 3 (2-3) | 3 (2-3) | 3 (3-3) | .372a |
aKruskal-Wallis test (low vs normal vs high TSH); bChi2 test. BI = Barthel Index, CRS-R = Coma Recovery Scale-Revised, EFA = Early Functional Abilities, fT3 = free triiodothyronine, fT4 = free thyroxine, GOS = Glasgow Outcome Scale, ICU = intensive care unit, IMC = intermediate care unit, LOS = length of stay, TSH = thyroid-stimulating hormone.
Univariate (unadjusted) and multivariate (adjusted) logistic regression for predictive factors of favorable outcome (GOS > 3).
| Independent variable | Unadjusted | Adjusted | ||||
|---|---|---|---|---|---|---|
| OR | CI 95% |
| OR | CI 95% |
| |
| Age | 0.96 | 0.95-0.98 | <.001 | 0.96 | 0.94-0.98 | <.001 |
| Male | 0.82 | 0.52-1.31 | .410 | |||
| Time since injury | 0.98 | 0.96-0.99 | .043 | |||
| Admission to ICU | 0.71 | 0.46-1.11 | .132 | |||
|
| ||||||
| Vascular | 0.96 | 0.63-1.49 | .867 | |||
| Traumatic | 0.72 | 0.46-1.13 | .157 | |||
| Anoxic | 3.26 | 1.24-8.56 | .017 | |||
| BI | 1.13 | 1.06-1.17 | <.001 | |||
| EFA | 1.10 | 1.08-1.13 | <.001 | 1.07 | 1.03-1.11 | <.001 |
| CRS-R | 1.15 | 1.11-1.18 | <.001 | |||
| Complications | 0.63 | 0.53-0.76 | <.001 | |||
| Hypophysis dysfunction | 0.54 | 0.18-1.64 | .276 | |||
| fT3 | 1.59 | 1.09-2.32 | .016 | |||
| fT4 | 1.28 | 0.57-2.86 | .554 | |||
| TSH | 1.09 | 1.02-1.17 | .013 | 1.11 | 1.02-1.22 | .021 |
aMann-Whitney U test (low vs normal fT3); bChi2 test. BI = Barthel Index, CRS-R = Coma Recovery Scale-Revised, EFA = Early Functional Abilities, fT3 = free triiodothyronine, fT4 = free thyroxine, GOS = Glasgow Outcome Scale, TSH = thyroid-stimulating hormone.